Home

Where to get Berubicin

This is a scan of a patient's glioblastoma in Berubicin's Phase 1 clinical trial where 44% of the patients showed a clinical response. Berubicin is one of the first anthracycline's that does not require a specific carrier to be able to cross over the blood brain barrier and get into the brain Berubicin is a 4'-O-benzylated analogue of the anthracycline derivative doxorubicin, with potential antineoplastic activity.Berubicin intercalates into DNA and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, as well as RNA and protein synthesis CNS Pharmaceuticals Inc. said the U.S. Food and Drug Administration has granted Fast Track Designation for its lead investigational drug, Berubicin, in the treatment of patients with recurrent. Berubicin Hydrochloride is the hydrochloride salt of the anthracycline derivative berubicin with potential antineoplastic activity. Berubicin intercalates into DNA and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. Unlike other anthracycline derivatives, this agent crosses the blood-brain barrier (BBB) CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor if phase 2 trials are positive

However, CNS' overall liabilities decreased marginally from $1,905,428 to $1,901,757 during the same period. Additionally, the Company was able to more than double its cash from $5,379,790 to $11,075,200 year-over-year. With this in mind, having received FDA approval, CNS' Berubicin is now on the fast track towards commercialization

The company said it will initiate its phase 2 trial during the first quarter of 2021 to investigate the efficacy of Berubicin in adults with Glioblastoma Multiforme who have failed first-line therapy Berubicin, a new drug being developed for the treatment of glioblastoma, may be able to actually access and treat glioblastoma cells in the brain, according to the drug's manufacturer. The drug — which belongs to a class of powerful anthracyclines - is the first of its kind to cross the blood-brain barrier and attack brain tumors directly. CNS Pharmaceuticals will initiate its trial during the first quarter of 2021 to investigate the effectiveness of Berubicin in adults with GBM who have failed first-line therapy. CNS has joined with WPD Pharmaceuticals on a Phase 1 test of Berubicin in Poland for pediatric brain tumors. That trial should be in progress right now Called Berubicin, it belongs to a class of drugs known as anthracyclines, which are among the most powerful anti-tumor medications ever discovered. Unlike other drugs in this category, Berubicin is able to pass through the blood barrier that protects the brain from dangerous toxins, striking directly at the cancer WPD Pharmaceuticals has reported positive data from the Phase I clinical trial of Berubicin drug to treat glioblastoma multiforme (GBM). The clinical trial of Berubicin drug, conducted by pharmaceutical company Reata Pharmaceuticals, found that a patient remained cancer-free

As previously announced, CNS completed synthesis of Berubicin Active Pharmaceutical Ingredient (API) and has now shipped API to two companies, Pii and BSP, that will prepare an injectable form of.. Berubicin, a powerful anthracycline, may be able to access and treat glioblastoma multiforme (GBM) cells in the brain. In phase 1 clinical trials, 44% of patients showed significant anti-tumor activity, according to a CNS Pharmaceuticals press release. GBM is the most common type of brain cancer, and has a poor prognosis

About Berubicin. Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 trial with Berubicin in GBM which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in progression-free survival Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic. Get instant alerts when news breaks on your stocks. We are passionate about driving Berubicin's development forward, creating value in the near- and long-term, and, most importantly, making. Berubicin is one of the first anthracycline's that does not require a specific carrier to be able to cross over the blood brain barrier and get into the brain. None of the drugs that require carriers have been shown to be effective in humans

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system,.. Berubicin was developed at the largest cancer treatment and research institute in the world, and has been shown to get across the blood brain barrier and kill brain tumor cells not reachable by. In simple terms, the BBB allows Berubicin access to the brain where it can make contact with, and destroy, cancer cells. Here is why the FDA could fast track Berubicin. First, Berubicin has been studied in depth because it was in pre-clinical and human clinical development for more than 15 years CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, sublicenses the compound Berubicin to WPD Pharmaceuticals for 30 countries mainly in Europe and Asia

CNS Pharmaceuticals - Berubici

The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer So Berubicin then is a very potent inducer of apoptosis, it's a very potent inhibitor of cell growth, it's a very efficient molecule because it crosses the blood-brain barrier in high concentrations, so we don't have to flood the body with this poison in order to get just a little bit into the brain

Berubicin C34H35NO11 - PubChe

Berubicin is the first to be able to accomplish this task, enabling CNS Pharmaceuticals to secure a unique position on the expanding brain tumor therapeutics market. The global brain tumor therapeutics sector was valued at $1.1 billion in 2019, and is expected to grow at a CAGR of 10%, reaching a total of $1.6 billion by 2025 ( https://ibn.fm. VANCOUVER, British Columbia, July 12, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the Company or WPD) a clinical-stage pharmaceutical company, is pleased. CNS Pharmaceuticals holds the exclusive worldwide license to the Berubicin chemical compound Berubicin is CNSP's lead, novel anthracycline candidate for the treatment of glioblastoma multiforme (GBM) that was the subject of a previously conducted Phase 1 clinical trial, which had a clinical benefit response rate of 44% CNSP has sublicensed Berubicin to WPD Pharmaceuticals in [ As previously announced, CNS completed synthesis of Berubicin Active Pharmaceutical Ingredient (API) and has now shipped API to two companies, Pii and BSP, that will prepare an injectable form of Berubicin ready for clinical use. This is an important step to allow CNS to initiate clinical studies in GBM patients VANCOUVER, British Columbia, July 12, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the Company or WPD) a clinical-stage pharmaceutical company, is pleased to announce that CNS Pharmaceuticals Inc. (CNS) (NASDAQ:CNSP), the company that licenses the drug candidate Berubicin to WPD for 29 countries mainly in Europe, announced that the U.S. Food and.

19 May 2021 CNS Pharmaceuticals intends to file additional patents relating to berubicin to further secure intellectual property protections. 19 May 2021 WPD Pharmaceuticals plans a phase II trial for Glioblastoma (In adults) in Poland (IV) in the second half of 2021. 18 May 2021 Phase-II clinical trials in Glioblastoma (Recurrent, Second-line. During 2021, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial (with extensive PK) in. Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by interfering. CNS Pharmaceuticals (CNSP.Q), the company that licenses the drug candidate Berubicin to WPD Pharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its lead investigational drug for the treatment of patients with recurrent glioblastoma multiforme (GBM). What is Glioblastoma (GBM)? Glioblastoma (GBM) is a fatal brain [ Berubicin's promising results demonstrated in the Phase 1 clinical trial build on sixty years of clinical experience with anthracyclines. Get pre-market outlook, mid-day update and after.

Get details about our clinical trials that are currently enrolling patients. View Clinical Trials . We are still testing and developing some novel treatments, such as berubicin, the first experimental anthracycline chemotherapy agent to penetrate the blood-brain barrier (RTTNews) - The U.S. Food and Drug Administration granted Fast Track Designation for CNS Pharmaceuticals Inc.'s (CNSP) lead investigational drug, Berubicin, for the treatment of patients with. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 trial with Berubicin in GBM which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in progression-free. Receiving Fast Track Designation from the U.S. FDA is a huge achievement in our advancement of Berubicin for the treatment of glioblastoma, the most aggressive, deadly, and treatment-resistant type of cancer that forms in the brain. If there were ever a disease where the unmet clinical need demands action, it is GBM

CNS Pharma Gets Fast Track Designation for Berubicin

Results from the trial will compare Berubicin to the current standard of care, with a 2 to 1 randomization of patients to receive either Berubicin or Lomustine. Mariusz Olejniczak, CEO of WPD commented, I am very pleased and excited about the development we have made on Berubicin both in the United States and in Europe During Phase 1 trials, Berubicin showed 44% of patients experienced a clinical benefit of stable disease or better, one being cancer-free after 14 years, and two patients reporting significant tumor reduction (up to 80%) Additional research to be conducted by sublicensee partner WPD Pharmaceuticals, Inc. in Poland, including the first-ever pediatric trial The glioblastoma multiforme. Berubicin - Novel anthracycline. CNS' lead product candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently. Our decision to contract both Pii and BSP represents a key part of our overall strategy to get Berubicin back into clinical trials as soon as possible, stated John Climaco, CEO of CNS. Berubicin was engineered specifically to be invisible to the efflux pumps in the blood-brain barrier. That's why we believe Berubicin, unlike other anthracyclines, appears to get across the blood-brain barrier and inside the brain to fight tumor cells

Clarithromycin, Clarithromycin Manufacturers & Suppliers

Berubicin hydrochloride C34H36ClNO11 - PubChe

Irinotecan Manufacturers, Irinotecan Suppliers, Irinotecan

CNS Pharmaceuticals is a clinical-stage pharmaceutical business working on anti-cancer medication candidates for the cure of brain and central nervous system tumors, both primary and metastatic. Berubicin, CNSP's primary medication candidate, is a new anthracycline that seems to penetrate the blood-brain barrier for the first time Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Suppor Mariusz Olejniczak, CEO of WPD comments, We are very pleased to continue working with Worldwide to further progress the clinical trials of Berubicin. Worldwide's world-class experience and. Get the Top 5 Stocks Now! Sponsored. Read More. Stay-at-Home Stocks Still A Healthy Investment? Best Solar Stocks To Buy As We Approach 2021; Berubicin is an anthracycline, a kind of anticancer medication that is one of the most potent and efficient against more cancer types than any other

Eric and Sid talk to John Climaco, Chairman and CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP). During the interview, John provided an overview of CNS Pharmaceuticals and recent FDA approval to begin clinical trials on the company's lead drug candidate, Berubicin, a proposed treatment for glioblastoma multiforme (GBM), an incurable brain cancer. The episode is around 20 minutes long and. CNS Pharmaceutical Inc. (NASDAQ: CNSP) announced its business update, including the recent launch of a pivotal study of its flagship program assessing Berubicin in adult Glioblastoma Multiforme (FB) treatment and expects to commence dosing in Q3 2021. Berubicin receives Fast Track Designation . The company received Fast track Designation for Berubicin from the FDA for recurrent GBM treatment Berubicin was developed by Dr Waldemar Priebe, professor of medicinal chemistry at The University of Texas MD Anderson Cancer Center, who took a different approach to attacking GBM than others, examining the precise biologic transport issue that has prevented efficacy in GBM in the past rather than solely focusing on the tumor itself Berubicin - Novel anthracycline. CNS' lead product candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications

As a part of the Berubicin development strategy, WPD has requested scientific advice on pre-clinical and clinical development from the European Medicines Agency (EMA). On March 24, 2021, WPD attended a Pre-Submission Meeting with EMA experts during which useful information was provided on the preparation of documentation for the upcoming. CNS' lead product candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier.Berubicin is currently in development for the treatment of a. VANCOUVER, British Columbia, June 28, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the Company or WPD) a clinical-stage pharmaceutical company, today provided an update on its Berubicin drug candidate clinical development program for the treatment of glioblastoma multiforme (GBM)

CNS Pharma turns to crowdfunding to advance glioblastoma

CNS Pharmaceuticals (CNSP

  1. Berubicin - CAS 677017-23-1 Catalog number: B2693-305412. berubicin hydrochloride is the hydrochloride salt of the anthracycline derivative berubicin with potential antineoplastic activity. Berubicin intercalates into DNA and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein.
  2. CNS Pharmaceuticals Inc.'s U.S. manufacturer, Pharmaceutics International Inc., has completed the manufacturing process for Berubicin Drug Product, its lead drug candidate for the treatment of glioblastoma multiforme (GBM), an aggressive form of brain cancer currently considered incurable. Completing the manufacturing process for Berubicin in the United States is an essential step in our.
  3. Plus, get special offers from Pharmaceutical Outsourcing - all delivered right to your inbox! Sign up now! The Company implemented a dual-track drug product manufacturing strategy to mitigate COVID-19-related delay risks, diversify its supply chain and provide for localized availability of Berubicin
  4. CNS Pharmaceuticals announced its European manufacturer, BSP Pharmaceuticals S.p.A. (BSP), has completed the manufacturing process for Berubicin Drug Product, its lead drug candidate for the treatment of glioblastoma multiforme (GBM), an aggressive form of brain cancer currently considered incurable
  5. istration granted Fast Track Designation for CNS Pharmaceuticals Inc.'s lead investigational drug, Berubicin, for the treatment of patients with recurrent glioblastoma multiforme or GBM.The Fast Track Designation enables more frequent interactions with the FDA to expedite the development and review process for drugs intended to treat serious or life-threatening.

FDA Approves CNS Pharma's IND Application For Brain Cancer

  1. CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, sublicenses the compound Berubicin to WPD Pharmaceuticals for 30 countries mainly in Europe and Asia. WPD, a clinical-stage pharmaceutical company, today provided an update on its Berubicin drug candidat
  2. Berubicin could be a total game changer, said Mr. Climaco. In fact, in Berubicin's Phase I clinical trial, a significant percentage of patients showed a clinical response. No anthracycline - the class of anticancer drugs to which Berubicin belongs - has ever been able to show anything like this based on this class of drugs' inability to get.
  3. e its effects on brain cancer cells that are resistant to temozolomide, which today is used as the standard chemotherapeutic. The project also provides for preclinical testing to deter
  4. No anthracycline - the class of anticancer drugs to which Berubicin belongs - has ever been able to show anything like this based on this class of drugs' inability to get into the brain
  5. Results will compare Berubicin to the current standard of care, with a 2 to 1 randomization of patients to either receive Berubicin or Lomustine. The trial's adaptive design is intended to allow an interim analysis of the data to demonstrate meaningful differences in efficacy between treatments and then to allow an adjustment to the size of the.
  6. Berubicin treatment of brain cancer patients appeared to demonstrate positive responses that include one durable complete response in a Phase 1 human clinical trial conducted by Reata Pharmaceuticals, Inc. Berubicin, was developed by Dr. Waldemar Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center
Ambroxol Hydrochloride Manufacturers, Ambroxol HCL

Berubicin was created at MD Anderson Cancer Center, the largest cancer and research institute in the world. Berubicin's Phase I clinical trial yielded promising results showing clinical activity in 44% of patients*. Berubicin is the first of its class of drugs to cross the blood brain barrier (BBB) and reach cancer cells in brain tumor patients CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44% CNS Pharmaceuticals Inc. (NASDAQ:CNSP) has its lead product candidate, Berubicin being studied for the treatment of glioblastoma multiforme (GBM). A couple of months ago, the company received an Orphan Drug Designation from the FDA for the anthracycline anticancer drug formerly known as RTA 744. This was after an investigation in a phase 1 study of [ WPD Pharmaceuticals plans to initiate a Berubicin Phase 2 adult GBM trial in the first half of 2021 and a multicenter pediatric malignant glioma Phase 1 clinical trial in 2021 CNS Pharmaceuticals. However, Berubicin is different. No anthracycline - the class of anticancer drugs to which Berubicin belongs - has ever been able to show anything like these results, based on this class of drugs' inability to get into the brain, said John M. Climaco, CEO, CNS Pharmaceuticals. This disease does not discriminate

Engineered Drug May Directly Fight Glioblastoma Tumor

CNS Pharmaceuticals, a biotechnology company specializing in the development of novel treatments for brain tumors, completed an agreement with Houston Pharmaceuticals, Inc. (HPI) to obtain the rights to a worldwide, exclusive royalty-bearing, license for the chemical compound commonly known as Berubicin VANCOUVER, British Columbia, June 28, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the Company or WPD) a clinical-stage pharmaceutical company, today provided an update on its Berubicin drug candidate clinical development program for the treatment of glioblastoma multiforme (GBM). Berubicin is an anthracycline, a class of anticancer agents that are. WPD Pharmaceuticals plans to initiate a Berubicin Phase 2 adult GBM trial in the first half of 2021 and a multicenter pediatric malignant glioma Phase 1 clinical trial in 2021 CNS Pharmaceuticals plans to initiate a Berubicin adult GBM trial in Q1 2021 HOUSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals (CSE:WBIO) (8SV1.F) (WPD) and CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (CNS. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 trial with.

Berubicin is a novel anthracycline and the first anthracycline to cross the blood-brain barrier. It is in development for the treatment of several serious brain and CNS oncology indications. Berubicin Supply Agreement with WPD Pharmaceuticals. On February 24, 2021, WPD Pharmaceuticals signed an agreement with CNSP to obtain an Investigational. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44% CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. The company was founded in 2017 and is headquartered in Houston, Texas. Organ Targeted Therapeutics The company's lead drug candidate, Berubicin, is proposed for the CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 clinical trial.

CNS Pharmaceuticals, Inc. stock rose after the Houston, Texas-based biopharmaceutical company announced that the U.S. Food and Drug Administration has granted Fast Track Designation for its lead investigational drug Berubicin, for the treatment of recurrent glioblastoma multiforme, a type of brain cancer. Shares of CNSP rose 4.98% and were. From Benzinga Mar 18, 2021. Gainers Upstart Holdings, Inc. (NASDAQ: UPST) jumped 68.6% to $102.50 after the company reported better-than-expected Q4 EPS and sales results and issued Q1 & FY21 sales.. If the campaign funding goal has been reached, the company may either: decide to close the campaign. In this instance, the company must. give investors at least 5 business days notice of their intention to. close; notify investors of the intention to conduct a rolling close, which. allows the company to draw down funds and continue to accept CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced its plans to issue a video update at 4:30 p.m. ET on Nov. 12, 2020, to discuss the clinical trial design for its upcoming Phase 2 U.S. trial for Berubicin

Berucibin Trial to Start in Early 2021 for GBM - Brain

For the readers interested in the stock health of CNS Pharmaceuticals Inc. (CNSP). It is currently valued at $2.21. When the transactions were called off in the previous session, Stock hit the highs of $2.11, after setting-off with the price of $2.091. Company's stock value dipped to $1.96 during. WPD Pharmaceuticals plans to initiate a Berubicin Phase 2 adult GBM trial in the first half of 2021 and a multicenter pediatric malignant glioma Phase 1 clinical trial in 2021. CNS Pharmaceuticals plans to initiate a Berubicin adult GBM trial in Q1 2021. HOUSTON, TX (Feb ruary 18, 2021) - WPD Pharmaceuticals (CSE:WBIO) (8SV1.F) (WPD) and CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (CNS or. Emaginos Featured in Syndicated NetworkNewsAudio Broadcast Covering Recent Filing of a Provisional Patent for Game-Changing EdManage Analytics Platform. Emaginos, a company in the business of transforming K-12 public education, announces that it has been featured in a broadcast via NetworkNewsAudio (NN... View Details Berubicin may change that history because it is the first anthracycline that, based on limited clinical data, appears to cross the blood-brain barrier and achieve drug levels critical for efficacy against central nervous system malignancies, he said

Instagram Toronto: Where To Get All The Instaworthy Photos

Breakthroughs Target the Killer Cancer Affecting McCain

  1. Veterans Guardian is an evidence-based medical claims consulting firm helping veterans win previously denied and new claims to get the VA benefits they deserve. At Veterans Guardian, giving back to the community is a core principle. The company currently supports 41 local and national charities. Learn more at VetsGuardian.com . About Veterans.
  2. Glioblastoma multiforme drug Berubicin receives positive
  3. CNS Pharmaceuticals Completes Drug Product Manufacturing
  4. Berubicin Breaches Blood-Brain Barrier to Attack Brain Tumor
CNS Pharmaceuticals Inc

FDA Grants Fast Track Designation to CNS Pharmaceuticals

Where to Get Your Coffee Fix in Memphis - Choose901

John Climaco, CEO of CNS Pharmaceuticals, Discusses New

  1. CNS Pharmaceuticals, Inc
  2. Clinical Trials for Evolving Targeted Therapies Fueling
  3. Berubicin - CNS Pharmaceuticals - AdisInsigh
  4. CNS Pharmaceuticals Berubicin Trial is On Schedule to
  5. US FDA grants fast track status to CNS Pharma's Berubicin
  6. Brain Tumors MD Anderson Cancer Cente
  7. FDA Grants Fast Track Designation To CNS's Berubicin For

CNS Pharmaceuticals Commences Patient Enrollment in

  1. Best Penny Stocks to Buy Right Now? 3 For Your Your July
  2. CNS Pharmaceuticals Inc (NASDAQ:CNSP) Receives IND
  3. CNS Pharmaceuticals NASDAQ: CNS
BioMedNewsBreaks — VistaGen Therapeutics Inc